The American Society of Gene & Cell Therapy (ASGCT) is the primary membership organization for scientists, physicians, professionals, and patient advocates involved in gene and cell therapy. The mission is to advance knowledge, awareness, and education leading to discovery and clinical application of gene and cell therapies to alleviate disease—this is done by serving as a catalyst to transform medicine by advancing gene and cell therapies to benefit patients and society. The 22nd Annual Meeting will be held in Washington, 29th April - 2nd May 2019.
Michael Roberts, CSO, will be presenting as part of the Tools & Technologies Forum on Monday 29th April at 10:45am - Mastering Gene Control to Enable the Next Generation of Gene Medicines.
You can also catch up on Synpromics’ work with our key industry and academic partners, incorporating our synthetic promoters in novel cell and gene therapies. Three posters are being presented at the conference:
Synpromics: Controlled gene expression in the liver: design of constitutive, inducible and repressible promoters for use in gene medicine
Session: Metabolic, Storage, Endocrine, Liver and Gastrointestinal Diseases II, Wednesday 1st May, 5 – 6 PM, Abstract number: 798.
UCL: Development of Novel Promoters for Neurological Gene Therapy
Session: Neurologic Diseases II, Tuesday 30th April, 5 – 6pm, Abstract number: 558.
Solid Biosciences: Identification of Novel Muscle-Specific Promoters for AAV Gene Expression in Skeletal and Cardiac Muscles
Session: Musculo-skeletal Diseases, Wednesday 1st May, 5 – 6pm , Abstract number: 822.
Experts from the Company will be on hand throughout the event to discuss our latest developments and plans for the future so get in touch if you’d like to arrange a meeting in Washington, DC.